Progyny Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Progyny Inc 's ROA in the third quarter of 2026?
Progyny Inc achieved a return on average assets (ROA) of 12.86 % in its third quarter of 2026, which is below Progyny Inc 's average return on assets, which stands at 14.47%.

Despite the company's net income deteriorating, Progyny Inc was able to improve its ROA compared to the second quarter of 2026.

However, within the Healthcare sector 90 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 674, from total ROA ranking in the second quarter of 2026 at 933.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-15.15 %	-5.93 %	-4.37 %	46.17 %	36.76 %
Y / Y Net Income Change	89.35 %	63.93 %	60.91 %	18.54 %	33.04 %
Net Income (TTM) in million	91	79	68	59	57
Return On Assets (TTM)	12.86 %	10.66 %	9.03 %	7.73 %	8.1 %
PGNY's Total Ranking	# 674	# 933	# 798	# 825	# 811
Total Assets (TTM) in million	675	716	698	742	795
Seq. Total Assets Change	-5.74 %	2.51 %	-5.94 %	-6.64 %	4.5 %
Seq. Net Income Change	-6.42 %	15.76 %	94.09 %	-9.95 %	-18.98 %

PGNY's 5 Years Annual ROA >> Back to PGNY Management Effectiveness >> Compare PGNY ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 5
Sector	# 91
Overall	# 569

Return On Assets Statistics
High	Average	Low
90.65 %	14.47 %	-6.62 %
(Mar 31 2020)		(Jun 30 2020)

Financial Statements
Progyny Inc 's Assets	$ 675 million	PGNY's Balance sheet
Progyny Inc 's Income	$ 26 million	Quarterly PGNY's Income Statement
PGNY's Income by Division		See PGNY's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	46.17 %	-23.9 %	44.73 %	63.52 %	41.42 %
Total Assets in million	742	508	668	461	282
Y / Y Net Income Change	7.7 %	-12.41 %	104.35 %	-53.84 %	41.56 %
Net Income in million	59	54	62	30	66
Annual Return On Assets	7.88 %	10.7 %	9.29 %	6.58 %	23.32 %

PGNY's 5 Years Annual ROA >> Back to PGNY Management Effectiveness >> Compare PGNY ROA to its Competitors

Comment on PGNY's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA deteriorated to 7.88 %, despite annual net income growth of 7.7 % to $58.52 million, from $54.34 million a year ago, as PGNY's assets increase to $742.44 million, by 7.7 %.

More Return On Assets Ratios
PGNY's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PGNY's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PGNY's Competitors
Subscribers only: Roa for Progyny Inc 's Suppliers
Subscribers only: Return On Assets for PGNY's Customers

You may also want to know
PGNY's Roi	PGNY's Inventory Turnover Ratio	PGNY's Growth Rates	PGNY's Dividend Comparisons
	PGNY's Profitability Ratios	PGNY's Asset Turnover Ratio	PGNY's Dividend Growth
PGNY's Roe	PGNY's Valuation Ratios	PGNY's Financial Strength Ratios	PGNY's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Qhslab Inc	22.59 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Protalix Biotherapeutics inc	19.89 %
Electromed Inc	19.73 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Alpha Pro Tech Ltd	12.46 %
Tenet Healthcare Corp	12.39 %

Date modified: 2026-11-06T12:59:56+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.